Concord Biotech Limited — Board Meeting, 11-11-2024: Outcome of Board Meeting

Concord Biotech Limited announced the approval of its unaudited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2024. Key highlights include a revenue of ₹32,020.68 lakhs, a profit after tax of ₹9,869.94 lakhs, and earnings per share of ₹9.43. The company's financial position shows total assets of ₹1,76,455.55 lakhs and equity of ₹1,59,058.99 lakhs. For further details, refer to the financial statements attached.